Key facts
- Imvaria’s last known valuation is $11.0M (Apr 2020).
- It has raised $3.0M; the latest was Later Stage VC in Jan 2026.
- Notable investors include MedTech Innovator, National Institutes of Health, StartX (US), Endless Frontier Labs, Kevin Moore — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Imvaria
- ·The full record, as it builds
Funding rounds
No funding rounds for Imvaria are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Imvaria
Developer of an AI-driven diagnostic software designed for noninvasive assessment of lung diseases. The company's software analyzes clinical imaging and lab data through a centralized, cloud-based lab system that processes cases across various data types and laboratory results to improve disease detection and reduce diagnostic delays, enabling healthcare providers and pulmonologists to gain earlier and accurate insights into complex conditions like interstitial lung diseases without the need for invasive procedures.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2019
- Employees
- 15
- Website
- imvaria.com/
- Ownership
- Privately Held (backing)
Imvaria doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Imvaria shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Imvaria in its N-PORT filings yet. We sweep new filings monthly.